Behavioral and neurogenomic transcriptome changes in wild-derived zebrafish with fluoxetine treatment

• Published in: BMC genomics 2013-05, Vol.14 (1), p.348-348
• Main Authors: Wong, Ryan Y, Oxendine, Sarah E, Godwin, John
• Format: Article
• Language: English
• Subjects: Animals; Anxiety; Anxiety - drug therapy; Anxiety - genetics; Behavior; Behavior, Animal - drug effects; Behavioral biology; Danio rerio; Dosage and administration; Experiments; Fluoxetine; Fluoxetine - chemistry; Fluoxetine - pharmacology; Fluoxetine - therapeutic use; Freshwater; Genetic aspects; Genetic engineering; Genetic transcription; Health aspects; Humans; Male; Nervous System - drug effects; Nervous System - metabolism; Neurogenetics; Physiological aspects; Prolactin; Rodents; Sequence Analysis, RNA; Serotonin; Serotonin Uptake Inhibitors - chemistry; Serotonin Uptake Inhibitors - pharmacology; Serotonin Uptake Inhibitors - therapeutic use; Stereoisomerism; Stress; Transcriptome - drug effects; Zebra fish; Zebrafish; Zebrafish - genetics
• ISSN: 1471-2164; 1471-2164
• DOI: 10.1186/1471-2164-14-348

Stress and anxiety-related behaviors are seen in many organisms. Studies have shown that in humans and other animals, treatment with selective serotonin reuptake inhibitors (e.g. fluoxetine) can reduce anxiety and anxiety-related behaviors. The efficacies and side effects, however, can vary between individuals. Fluoxetine can modulate anxiety in a stereospecific manner or with equal efficacy regardless of stereoisomer depending on the mechanism of action (e.g. serotonergic or GABAergic effects). Zebrafish are an emerging and valuable translational model for understanding human health related issues such as anxiety. In this study we present data showing the behavioral and whole brain transcriptome changes with fluoxetine treatment in wild-derived zebrafish and suggest additional molecular mechanisms of this widely-prescribed drug. We used automated behavioral analyses to assess the effects of racemic and stereoisomeric fluoxetine on male wild-derived zebrafish. Both racemic and the individual isomers of fluoxetine reduced anxiety-related behaviors relative to controls and we did not observe stereospecific fluoxetine effects. Using RNA-sequencing of the whole brain, we identified 411 genes showing differential expression with racemic fluoxetine treatment. Several neuropeptides (neuropeptide Y, isotocin, urocortin 3, prolactin) showed consistent expression patterns with the alleviation of stress and anxiety when anxiety-related behavior was reduced with fluoxetine treatment. With gene ontology and KEGG pathway analyses, we identified lipid and amino acid metabolic processes, and steroid biosynthesis among other terms to be over-enriched. Our results demonstrate that fluoxetine reduces anxiety-related behaviors in wild-derived zebrafish and alters their neurogenomic state. We identify two biological processes, lipid and amino acid metabolic synthesis that characterize differences in the fluoxetine treated fish. Fluoxetine may be acting on several different molecular pathways to reduce anxiety-related behaviors in wild-derived zebrafish. This study provides data that could help identify common molecular mechanisms of fluoxetine action across animal taxa.